

# Strategic Collaboration with Amgen to develop MP0310

*Patrick Amstutz, CEO*

Webcast of Molecular Partners AG, Switzerland (SIX: MOLN)

December 19, 2018

# Molecular Partners: A Swiss Biotech by the Numbers

**1 TRILLION**  
DARPin® modules in our library



**71** ISSUED  
PATENTS

**130** TEAM  
MEMBERS




**8** % GROWTH IN FTE  
since 2017, nearly all in R&D

**4** DEVELOPMENT  
DARPin® candidates




**1.8+k** PATIENTS TREATED  
to date in clinical trials

# A balanced and robust portfolio



AMD: age-related macular degeneration; DME: diabetic macular edema; NSCLC: non-small cell lung cancer

# MP0310 (FAP x 4-1BB): Activating T cells in the Tumor



MP0310 is a multi-specific DARPin® designed to improve the efficacy and safety of 4-1BB co-stimulation via:

- **Tumor-localized binding to FAP**
- **Clustering of 4-1BB via FAP binding to maximize 4-1BB agonism**



Local 4-1BB activation has the potential to stimulate tumor-local T-cells





MP0310 has the potential to synergize with a range of other IO approaches


HSA, human serum albumin.

# Our Vision for MP0310: Expand the Therapeutic Window Through Tumor-Localized Immune Modulation

Many current IO therapeutics that activate the immune system throughout the body




Tumor-localized IO therapeutics that activate immune cells preferentially within the tumor



# DARPin® Toolbox: Tumor-Localized Immune Modulators

Tumor-localized immune modulators – overcoming the limitation of systemic side effects



		Immune Modulator			
		OX-40	4-1BB	CD40	Other Targets
Localizer	Solid Tumor TAA*		TAA x 4-1BB		
	Tumor Stromal Antigen		<b>FAP x 4-1BB MP0310</b>	<b>FAP x CD40</b>	
	Hematologic TAA	TAA x OX40	TAA x 4-1BB	TAA x CD40	

MP0310 is the first DARPin® candidate from our DARPin® IO toolbox

\*Tumor-Associated Antigen (TAA)

# Amgen Collaboration



# AMGEN AT ASH 2018: ADVANCING A PORTFOLIO OF NOVEL, HIGH-POTENTIAL CANCER THERAPIES

## WE ARE RAPIDLY ADVANCING MANY NOVEL, HIGH-POTENTIAL ONCOLOGY PROGRAMS

Multiple Myeloma	Leukemia		Solid Tumors	
KYPROLIS® proteasome inhibitor	BLINCYTO® CD19 BiTE®	ALL	IMLYGIC® oncolytic virus	Melanoma
AMG 420 BCMA BiTE®	AMG 562 CD19 HLE-BiTE®		AMG 509* prostate bispecific Ab (XmAb®)	Prostate
AMG 701 BCMA HLE-BiTE®	AMG 330 CD33 BiTE®	AML	AMG 160* PSMA HLE-BiTE®	Small Cell Lung Cancer
AMG 424 CD38 bispecific Ab (XmAb®)	AMG 673 CD33 HLE-BiTE®		AMG 757 DLL3 HLE-BiTE®	
AMG 176 MCL-1 inhibitor (iv)	AMG 427 FLT3 HLE-BiTE®		AMG 119 DLL3 CAR T	
AMG 397 MCL-1 inhibitor (oral)	AMG 553* FLT3 CAR T		AMG 510 KRAS G12C inhibitor	Solid Tumors
	AMG 176 MCL-1 inhibitor (iv)		AMG 199* HLE-BiTE®	Gastric
	AMG 397 MCL-1 inhibitor (oral)	AMG 910* HLE-BiTE®		

\*Preclinical/not yet enrolling patients; BCMA = B-cell maturation antigen; BiTE® = bispecific T-cell engager; Ab = antibody; Mcl-1 = myeloid cell leukemia-1; iv = intravenous; HLE = half-life extended; FLT3 = fms-like tyrosine kinase 3; CAR T = chimeric antigen receptor enhanced T cells; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; PSMA = prostate-specific membrane antigen; DLL3 = delta-like 3

Provided December 3, 2018, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

7

Bispecific  
Small Molecule/Other



# Molecular Partners and Amgen Close Strategic Collaboration for Development of MP0310

- **Why Amgen:**
  - Amgen has strong pipeline of IO drug candidates that have the potential to synergize with MP0310
- **Deal Structure:**
  - Collaboration and license agreement for the development of MP0310 DARPin® candidate
  - Co-funding of clinical development:
    - Parties will share costs in defined percentages for first 3 indications subject to certain conditions
    - For all additional clinical trials, Amgen is responsible for all development costs
  - MP retains certain rights to develop and commercialize its own products in combination with MP0310
- **Financials:**
  - USD 50mio upfront
  - USD 497mio in clinical, regulatory and commercial milestones
  - Double digit, tiered royalties up to high teens

# Our Accelerating Progress

## 2018 Achievements



Abicipar phase 3 data



MP0250 initial activity in MM; NSCLC ongoing



Second oncology DARPin<sup>®</sup> molecule in the clinic (MP0274)



IO DARPin<sup>®</sup> portfolio progress → 10 abstracts at AACR and SITC



Strengthening of oncology team

## 2019 Growth

MAPLE trial: results with further optimized formulation

Multiple safety & efficacy readouts in 2019

Enrollment, initial efficacy in 2019

Continued expansion and advancement toward the clinic

Acceleration of clinical activities

# Questions



# Disclaimer



This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares.

This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like “potential”, “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements.

Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG’s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith.


The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit.

# DARPin® Strategy in Oncology




# Combined Therapy with MP0310 and a TAA x CD3 Bi-Specific Results in a Significant Increase of Intratumoral CD8+ T Cells

## FAP-Mediated Tumor Accumulation of MP0310




HT-29 tumor-implanted NSG mice


## Intratumoral CD8 T cells




## Tumor growth inhibition PBMC humanized HT-29 xenograft model




# MP0310 Induces CD8+ T Cell Accumulation




TAA x CD3  
0.05mg/kg





Stroma-rich area



Stroma-poor area




TAA x CD3  
0.05mg/kg  
+  
mFAP x 4-1BB  
1.6mg/kg



HT-29 tumor implanted NSG mice

# MP0310 Suitable for Multiple Combinations and Indications

## Potential combination partners



Molecular Partners AG

Wagistrasse 14

8952 Zürich-Schlieren

Switzerland

[www.molecularpartners.com](http://www.molecularpartners.com)

T +41 44 755 77 00

